Hutchmed China has voluntarily withdrawn its supplemental new drug application (NDA) in China for the use of fruquintinib in ...

(RTTNews) - Rhythm Pharmaceuticals (RYTM) announced the FDA has accepted the company's supplemental New Drug Application for IMCIVREE, a melanocortin-4 receptor agonist, for the treatment of ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 7.4% in the last trading session to close at $53.17. The move was backed by solid volume with far more shares changing hands than in a normal session.

has approved its Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication for heart failure patients. At approval, FUROSCIX was only indicated for the treatment of ...

Is Syndax Pharmaceuticals, Inc. a buy after the recent stock decline? Analysts support, upcoming approvals, but expect a ...

ARS Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) for a1 mg dose of nasal spray neffy, to treat ...

After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...

Organon (OGN) on Wednesday agreed to acquire Roivant Sciences' (ROIV) immuno-dermatology subsidiary, Dermavant, in a deal worth up to $1.2 billion. The healthcare company will pay $175 million upfront ...

Aurobindo Pharma Ltd announced that its subsidiary, Eugia Steriles Private Limited, received its first product approval from ...

The FDA approved Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL), Aurobindo Pharma said ...

(Sharecast News) - Hutchmed China has voluntarily withdrawn its supplemental new drug application (NDA) in China for the use of fruquintinib in combination with paclitaxel for second-line ...